Profile data is unavailable for this security.
About the company
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
- Revenue in USD (TTM)0.00
- Net income in USD-64.66m
- Incorporated2017
- Employees41.00
- LocationAN2 Therapeutics Inc1800 El Camino Real, Suite DMENLO PARK 94025-3069United StatesUSA
- Phone+1 (650) 331-9090
- Websitehttps://www.an2therapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipocine Inc | 4.80m | -8.49m | 28.34m | 17.00 | -- | 1.34 | -- | 5.90 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
ImmuCell Corp | 23.22m | -4.05m | 28.67m | 74.00 | -- | 1.22 | -- | 1.23 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Curis Inc | 10.16m | -47.57m | 29.95m | 48.00 | -- | -- | -- | 2.95 | -8.24 | -8.24 | 1.76 | -0.1175 | 0.1509 | -- | 4.12 | 211,687.50 | -70.62 | -37.25 | -90.04 | -41.12 | 98.30 | 96.05 | -468.18 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Quince Therapeutics Inc | 0.00 | -53.12m | 30.29m | 32.00 | -- | 0.645 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
Elevation Oncology Inc | 0.00 | -39.70m | 30.88m | 29.00 | -- | 0.3528 | -- | -- | -0.8399 | -0.8399 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -35.30 | -- | -37.14 | -- | -- | -- | -- | -- | -- | -25.25 | 0.2765 | -- | -- | -- | 51.93 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -64.66m | 31.04m | 41.00 | -- | 0.3154 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Lumos Pharma Inc | 1.49m | -35.75m | 31.28m | 33.00 | -- | 3.04 | -- | 21.05 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 31.42m | 163.00 | -- | 0.154 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Ocean Biomedical Inc | 0.00 | -98.59m | 31.57m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
FibroGen Inc | 173.82m | -168.32m | 32.97m | 486.00 | -- | -- | -- | 0.1897 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 33.06m | 73.00 | -- | 0.9894 | -- | 14.03 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -7.31m | 33.54m | -- | -- | 7.87 | -- | -- | -0.1977 | -0.1977 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -195.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Mar 2024 | 5.55m | 18.61% |
Octagon Capital Advisors LPas of 13 Jun 2024 | 3.01m | 10.09% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.56m | 5.22% |
BVF Partners LPas of 31 Mar 2024 | 1.24m | 4.16% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.22m | 4.09% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.15m | 3.86% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.04m | 3.49% |
Adage Capital Management LPas of 31 Mar 2024 | 312.62k | 1.05% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 283.60k | 0.95% |
Ghost Tree Capital LLCas of 31 Mar 2024 | 219.33k | 0.74% |